

**Microwave assisted copper (I) catalyzed A<sup>3</sup> cascade coupling of imidazo[1,2-*a*]pyridines via C-H bond functionalization as selective COX-2 inhibitors, antioxidants and *in silico* studies**

Aravind R. Nesaragi<sup>1,2</sup>, Ravindra R. Kamble<sup>1\*</sup>, Swati R. Hoolageri<sup>1</sup>, Shruti Dixit<sup>3</sup>, Shrinivas D. Joshi<sup>4</sup>, Shyamkumar Vootla<sup>3</sup>, Vijay M. Kumbar<sup>5</sup>


<sup>1</sup>Department of Studies in Chemistry, Karnatak University Dharwad -580003, India

<sup>2</sup>Centre for Nano and Material Sciences, Jain (Deemed-to-be University), Jain Global Campus, Kanakapura, Bangalore-562112, Karnataka, India


<sup>3</sup>Department of Biotechnology and Microbiology, Karnatak University Dharwad -580003, India

<sup>4</sup>Novel Drug Design and Discovery Laboratory, Department of Pharmaceutical Chemistry, S.E.T.'s College of Pharmacy, Dharwad -580002, India


<sup>5</sup>Central Research Laboratory, Maratha Mandal's NGH Institute of Dental Sciences and Research Centre, Belagavi - 590010, India




**Spectrum No. 1  $^1\text{H}$  NMR spectrum of compound 8e (DMSO- $d_6$ , 400 MHz)**




**Spectrum No. 2  $^1\text{H}$  NMR spectrum (expansion) of compound 8e (DMSO- $d_6$ , 400 MHz)**




Spectrum No. 3  $^{13}\text{C}$  NMR spectrum of compound 8e (DMSO-  $d_6$ , 100 MHz)




Spectrum No. 4 LC of compound 8e




**Spectrum No. 5** Mass spectrum of compound 8e




**Spectrum No. 6** <sup>1</sup>H NMR spectrum of compound 8i (DMSO- *d*<sub>6</sub>, 400 MHz)




**Spectrum No. 7  $^1\text{H}$  NMR spectrum (expansion) of compound 8i (DMSO-  $d_6$ , 400 MHz)**




**Spectrum No. 8  $^{13}\text{C}$  NMR spectrum of compound 8i (DMSO-  $d_6$ , 100 MHz)**




**Spectrum No. 9 LC of compound 8i**




**Spectrum No. 10 Mass spectrum of compound 8i**




**Spectrum No. 11**  $^1\text{H}$  NMR spectrum of compound 8k (DMSO-  $d_6$ , 400 MHz)



**Spectrum No. 12**  $^1\text{H}$  NMR spectrum (expansion) of compound 8k (DMSO-  $d_6$ , 400 MHz)




**Spectrum No. 13** <sup>13</sup>C NMR spectrum of compound 8k (DMSO- *d*<sub>6</sub>, 100 MHz)




**Spectrum No. 14** LC of compound 8k







**Spectrum No. 15** Mass spectrum of compound 8k




**Spectrum No. 16** <sup>1</sup>H NMR spectrum of compound 8m (DMSO-*d*<sub>6</sub>, 400 MHz)




Spectrum No. 17 <sup>13</sup>C NMR spectrum of compound 8m (DMSO- *d*<sub>6</sub>, 100 MHz)




Spectrum No. 18 LC of compound 8m




**Spectrum No. 19** Mass spectrum of compound 8m




**Spectrum No. 20**  $^1\text{H}$  NMR spectrum of compound 8n (DMSO- $d_6$ , 400 MHz)




**Spectrum No. 21  $^1\text{H}$  NMR spectrum (expansion) of compound 8n (DMSO-  $d_6$ , 400 MHz)**




**Spectrum No. 22  $^{13}\text{C}$  NMR spectrum of compound 8n (DMSO-  $d_6$ , 100 MHz)**




**Spectrum No. 23 LC of compound 8n**




**Spectrum No. 24 Mass spectrum of compound 8n**




Spectrum No. 25 <sup>1</sup>H NMR spectrum of compound 8o (DMSO-*d*<sub>6</sub>, 400 MHz)




Spectrum No. 26 <sup>13</sup>C NMR spectrum of compound 8o (DMSO-*d*<sub>6</sub>, 100 MHz)




**Spectrum No. 27 LC of compound 8o**



**Spectrum No. 28 Mass spectrum of compound 8o**




**Spectrum No. 29** <sup>1</sup>H NMR spectrum of compound 8q (DMSO-*d*<sub>6</sub>, 400 MHz)




**Spectrum No. 30** <sup>13</sup>C NMR spectrum of compound 8q (DMSO-*d*<sub>6</sub>, 100 MHz)







**Spectrum No. 31 LC of compound 8q**




**Spectrum No. 32 Mass spectrum of compound 8q**




Spectrum No. 33  $^1\text{H}$  NMR spectrum of compound 8s (DMSO- $d_6$ , 400 MHz)




Spectrum No. 34  $^1\text{H}$  NMR spectrum (expansion) of compound 8s (DMSO- $d_6$ , 400 MHz)




**Spectrum No. 35** <sup>13</sup>C NMR spectrum of compound 8s (DMSO- *d*<sub>6</sub>, 100 MHz)




**Spectrum No. 36** LC of compound 8s




**Spectrum No. 37** Mass spectrum of compound **8s**




**Spectrum No. 38**  $^1\text{H}$  NMR spectrum of compound **8u** (DMSO- $d_6$ , 400 MHz)




Spectrum No. 39  $^{13}\text{C}$  NMR spectrum of compound 8u (DMSO-  $d_6$ , 100 MHz)




Spectrum No. 40 LC of compound 8u




**Spectrum No. 41 Mass spectrum of compound 8u**




**Spectrum No. 42 <sup>1</sup>H NMR spectrum of compound 8v (DMSO- *d*<sub>6</sub>, 400 MHz)**



**Spectrum No. 43  $^{13}\text{C}$  NMR spectrum of compound 8v (DMSO- $d_6$ , 100 MHz)**



**Spectrum No. 44 LC of compound 8v**



**Spectrum No. 45 Mass spectrum of compound 8v**

### ***Biological Evaluation***

#### ***In vitro COX-2 assay***

*In vitro* COX-2 inhibition was carried out by using human COX-2 Elisa kit and following the manufacture's instructions. Supernatant liquid (100  $\mu$ L) collected was added into each well in duplicate (control and treated sample) and incubated for 2.5 hours at room temperature. The solution was discarded and washed 4 times with 1x wash solution. After the last wash, the remaining wash buffer was removed by pirating or decanting. The plate was inverted and blotted against clean paper towels. 1x prepared biotinylated antibody (100  $\mu$ L) was added to each well and incubated for 1 hour at room temperature with gentle shaking and the solution was discarded. Washing step was repeated as described above. Streptavidin solution (100  $\mu$ L) was added to each well and incubated for 45 minutes at room temperature with gentle shaking and the solution was discarded. The washing step was repeated and TMB One-Step Substrate Reagent (100  $\mu$ L) was added to each well and incubated for 30 minutes at room temperature in the dark with gentle shaking. Stop Solution (50  $\mu$ L) was added to each well and read at 450 nm immediately.

ATP-2Na solution (40 mM, 10  $\mu$ L) was added into each well and mixed thoroughly followed by incubation for 30 min at 37°C. The samples were removed and wells were washed 3



times with wash buffer. Blocking solution (100  $\mu$ L) was added into each well and incubated for 30 min at 37°C. Blocking solution was discarded and then 50  $\mu$ l of Anti-phosphotyrosine - HRP solution was added into each well and incubated for 30 min at 37°C. The antibody solution was discarded and each well was washed 4 times using washing buffer. Then HRP substrate solution (100  $\mu$ l) (TMBZ) was added into each well and incubated it for 30 min at 37°C and stop solution (100  $\mu$ l) was added into each well in the same order as HRP substrate solution. The absorbance was measured at 450 nm with a plate reader. % Inhibition was calculated as follows:

$$\% \text{ Inhibition} = (\text{Abs of sample} / \text{Abs of control}) \times 100$$

Using graph Pad Prism Version 5.1 the IC<sub>50</sub> of compounds was calculated by taking percentage of inhibition v/s COX-2 at five different concentrations of treatment.

### ***Scavenging activity using the DPPH method***

The stock solution of DPPH (3.94 mg in 100ml methanol) stored at 4° C until use. Then, DPPH (2 ml) solution was mixed with 1 ml of five different concentrations (20, 40, 60, 80 and 100  $\mu$ g mL<sup>-1</sup>) of the samples and standard respectively. A mixture of distilled water (1 ml) and DPPH (2 ml) solution was used as the control. The reaction mixture was mixed and kept in the dark for 30 min and incubated at room temperature. The absorbance was recorded spectrophotometrically at 517 nm. An antioxidant activity was calculated based on the percentage of DPPH radical scavenged using the following equation.

$$\text{Scavenging effect \%} = \frac{[\text{Control absorbance} - \text{Sample absorbance}]}{[\text{Control absorbance}]} \times 100$$

### ***Molecular docking assay***

The crystal structures of Mefenamic Acid Bound to Human Cyclooxygenase-2 (PDB ID: 5IKR; A chain) for the docking studies, obtained from the Protein Data Bank (X-Ray Diffraction, 2.34 Å). The protein was prepared for docking by adding polar hydrogen atom with Gasteiger-Huckel [29] charges and water molecules were removed. The 3D structure of the ligands was generated by the SKETCH module implemented in the SYBYL program (Tripos Inc., St. Louis, USA) and its energy-minimized conformation was acquired with the help of Tripos force field using Gasteiger-Huckel charges and molecular docking was performed with Surflex-Dock program which is interfaced with Sybyl-X 2.0 [30] and other miscellaneous parameters were assigned with the default values provided by the software.